Skip to main content
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      1 week 2 days ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
      STOP RA Cellular & Serologic Predictors

      Dr. Jack Cush discusses abstract 0774, "Longitudinal peripheral blood mult

      Dr. John Cush RheumNow

      1 week 2 days ago
      STOP RA Cellular & Serologic Predictors Dr. Jack Cush discusses abstract 0774, "Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future RA conversion", presented at #ACR25 https://t.co/fS3sFmQJIh https://t.co/V1dVHhUeqF
      New insights into Pre-RA: It ranges from asymptomatic individuals with ACPA positivity to those with symptomatic pre-cli

      Dr. John Cush RheumNow

      1 week 2 days ago
      New insights into Pre-RA: It ranges from asymptomatic individuals with ACPA positivity to those with symptomatic pre-clinical synovitis. Predicting who will develop RA is difficult, and there is a need for reliable biologic tools. Focusing on high-risk patients could https://t.co/SPOP7f0t7y
      When every option fails, bold moves remain.

      In 5 multi-resistant RA pts, TNFi + JAKi combo brought remission in most w

      Jiha Lee JihaRheum

      1 week 2 days ago
      When every option fails, bold moves remain. In 5 multi-resistant RA pts, TNFi + JAKi combo brought remission in most without major AEs. Not standard, not risk-free, but in young, low-infection-risk pts, it may offer a path forward. @RheumNow #ACR25 Abstract#2272
      #ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 2 days ago
      #ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in IL-2 as s/c every other day for 12 wks, followed by weekly for another 12 wks vs PBO. Efficacy & T-regs expansion were dose dependent. On to Phase 3 @RheumNow https://t.co/L0rYr5D1R1
      Post hoc eval of relapses from MANDARA, MEPO vs BEN in EGPA

      30% of pts had relapse, 81% of which were asthma +/- sinona

      Mike Putman EBRheum

      1 week 2 days ago
      Post hoc eval of relapses from MANDARA, MEPO vs BEN in EGPA 30% of pts had relapse, 81% of which were asthma +/- sinonasal disease Remainder were mostly muscle involved, only a few mononeuritis Mostly as expected; useful epi data for clinic #ACR25 @RheumNow Abstr#1769 https://t.co/IKKolMZJlF
      Gladman et al. PsA patients treated with guselkumab in DISCOVER-2. Male patients had more radiographic progression. Male

      Richard Conway RichardPAConway

      1 week 2 days ago
      Gladman et al. PsA patients treated with guselkumab in DISCOVER-2. Male patients had more radiographic progression. Males exhibit stronger relationship between early joint response and lower subsequent rates radiographic progression. @RheumNow #ACR25 Abstr#2345 https://t.co/TSNwesvPzj
      Mulcaire-Jones et al. Changes in PFTs over 1 year in early RA. Improved 31%, worsened 25%. No difference based on baseli

      Richard Conway RichardPAConway

      1 week 2 days ago
      Mulcaire-Jones et al. Changes in PFTs over 1 year in early RA. Improved 31%, worsened 25%. No difference based on baseline disease activity, or MTX use. Those with baseline ILD were MORE likely to improve. ?due to effect of treatment @RheumNow #ACR25 Abstr#2235 https://t.co/bJeLYN9oN7
      EGPA relapse in MANDARA including OLE

      Majority of relapses are asthma / sinonasal in nature

      Of non-airway:
      - arthralgi

      Brian Jaros, MD Dr_Brian_MD

      1 week 2 days ago
      EGPA relapse in MANDARA including OLE Majority of relapses are asthma / sinonasal in nature Of non-airway: - arthralgia/myalgia - sensory peripheral neuropathy @RheumNow #ACR25 Abst1769 https://t.co/cPjjzl4RWS
      CAR T flex for myositis 💪LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis✅ Well-tolerated (low-grade CRS,

      Akhil Sood MD, MS AkhilSoodMD

      1 week 2 days ago

      CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f

      Punjadath et al. Predictors of progression palindromic rheumatism to RA. 30 patients. 47% progressed to RA. Total number

      Richard Conway RichardPAConway

      1 week 2 days ago
      Punjadath et al. Predictors of progression palindromic rheumatism to RA. 30 patients. 47% progressed to RA. Total number of joints involved, RF, CRP predicted progression univariate. Only total joints significant in mutlivariate but underpowered. @RheumNow #ACR25 Abstr#2261 https://t.co/FtVKdGtEr9
      ×